 Home > Biochemical Engineering > Polypeptide > Nicotinamide mononucleotide for Sale > β-Nicotinamide Mononucleotid

β-Nicotinamide Mononucleotid buy - large image1

β-Nicotinamide Mononucleotid buy - image1

β-Nicotinamide Mononucleotid buy - image2

β-Nicotinamide Mononucleotid buy - image3

β-Nicotinamide Mononucleotid buy - image4

β-Nicotinamide Mononucleotid

TDS 61 Inquiries

Unit Price: Get Latest Price 

CAS No.:

1094-61-7

Grade:

Food Grade

Content:

Port:

hongkong

Brand:

Packaging:

box

Price valid (until):

2025-06-28

Contact Supplier

 Chat Now

Hong Kong Lemite Group Limited

Company Type:

Trader

Location:

Hongkong, China

Qualification:

Main Products:

Peptides

 Visit Store

Product Description
Seller Information
Inquiry History

Description

Product Detail

Description

Retatrutide (LY3437943)Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy. was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.vApixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.

Items	Specifications
Items	Specifications
Product Name	Retatrutide
CAS NO.	2381089-83-2
Appearance	white powder
Storage	Cool Dry Place

Certificates

Basic Info

Product Name:

Nicotinamide mononucleotide

Other Name:

Pyridinium,3-(aminocarbonyl)-1-(5-O-phosphono-β-D-ribofuranosyl)-,inner salt;Pyridinium,3-carbamoyl-1-β-D-ribofuranosyl-,hydroxide,5′-(dihydrogen phosphate),inner salt;Pyridinium,3-(aminocarbonyl)-1-(5-O-phosphono-β-D-ribofuranosyl)-,hydroxide,inner salt;3-Carbamoyl-1-β-D-ribofuranosylpyridinium hydroxide,5′-phosphate,inner salt;Nicotinamide mononucleotide;Nicotinamide ribonucleotide;NMN;Nicotinamide ribotide;β-NMN;Nicotinamide ribonucleoside 5′-phosphate;NMN (mononucleotide);β-D-NMN;27626-81-9;1140909-84-7

CAS No.:

1094-61-7

Molecular Formula:

C11H15N2O8P

InChIKeys:

InChIKey=DAYLJWODMCOQEW-TURQNECASA-N

Molecular Weight:

334.22

Exact Mass:

334.056610

EC Number:

214-136-5

UNII:

2KG6QX4W0V

Categories:

Polypeptide

Characteristics

PSA:

166

XLogP3:

-3.5

Storage Conditions:

2-8°C

Collision Cross Section:

165.2 Å² [M]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|165.2 Å² [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|167.13 Å² [M+H]+ [CCS Type: DT, Method: stepped-field]|166 Å² [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|165.8 Å² [M+H]+

See More Nicotinamide mononucleotide Properties 

Hazard Identification

Classification of the substance or mixture

no data available

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)	no data available
Signal word	no data available
Hazard statement(s)	no data available
Prevention	no data available
Response	no data available
Storage	no data available
Disposal	no data available

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Nicotinamide mononucleotide Safety Data Sheet 

Seller Information

Business Type:
Trader

Main Products:
Peptides

Location:
Room 5003, 5th Floor, Yau Lee Centre, 45 Yuen Yuen Road, Kwun Tong, Hong Kong

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Total Annual Revenue:
Less than $1 million

Total Employees:
5-10

Year of Establishment:
2024

Inquiry History

61 Inquiries

Country	Product	Purchase Quantity	Date Posted
Australia	NMN β-Nicotinamide Mononucleotide 1094-61-7 99.5% Uthever	50 KG	Nov 17, 2023
United Kingdom	NMN β-Nicotinamide Mononucleotide 1094-61-7 99.5% Uthever	100 MT	Aug 10, 2023
Philippines	β-NMN bulk powder 1094-61-7 Purity 99.9% food grade Beta Nicotinamide Mononucleotide powder	500 G	Jul 17, 2025
India	Beta-Nicotinamide Mononucleotide	1 KG	Jan 19, 2026
Russia	NMN	10 KG	Aug 4, 2023
India	NMN	1.00 KG	Dec 21, 2023
India	Nicotinamide mononucleotide	50 G	Apr 8, 2026
United States	NMN	100 G	Mar 14, 2026
India	Niacinamide	75.00 KG	Feb 25, 2026
Australia	NMN	1 KG	Feb 21, 2026
Indonesia	Nicotinamide mononucleotide NMN	1 KG	Oct 13, 2025
Australia	NMN	1 KG	Nov 1, 2024
United States	β-Nicotinamid Mononucleotide	1 KG	Sep 26, 2024
South Korea	b-NMN	1 KG	May 30, 2024
Vietnam	NMN	1 MT	May 24, 2024
United States	NMN	1 MT	Mar 7, 2024
Australia	NMN	50 KG	Dec 12, 2023
Peru	NMN	1 KG	Nov 29, 2023
Mexico	NMN	5 KG	Oct 25, 2023
Romania	NMN	1 KG	Sep 5, 2023

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Supplier Name	Details
β-Nicotinamide Mononucleotide, nmn, NMN 99% white powder 1094-61-7 Senwayer	Pharmaceutical Grade/99	Dingwang Technology (Wuhan) Co., Ltd.	Inquiry
High Quality 99% Purity of β-Nicotinamide Mononucleotide CAS NO 1094-61-7 ISO 9001:2005 REACH Verified Producer	Industrial Grade/99	Shaanxi Dideu Medichem Co. Ltd	Inquiry
Anti-Aging 99% High Purity Nmn Factory Bulk Powder Raw rich Stcock!	Pharmaceutical Grade/99	Hebei Shunxing Import and Export Co.,Ltd	Inquiry
Factory Nicotinamide Mononucleotide CAS 1094-61-7 NMN 99% Purity	Pharmaceutical Grade/99	Jinan Silk Road Trading Co., Ltd	Inquiry
NMN / β-Nicotinamide Mononucleotide	Food Grade/99.5	Wuhan BJM Pharm Inc.	Inquiry